General Description

Altamira Therapeutics

Youtube Subscribe

Ticker: CYTO

Sector: Biotechnology

Altamira Therapeutics reported earnings per share of -$28.20.20. Core of business will be out-licensing the technology to other biopharmas to use with internal programs. Historically substantial investor versus IDF.

Extended Summary

Altamira Therapeutics

Altamira Therapeutics reported earnings per share of -$28.20.20. The core of the business will be out-licensing the technology to other biopharmas to use with their internal programs. The company will host an Investor and Business Update Call on December 11, 2023, 8:30 a.m. Altamira Therapeutics is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infection (Bentrio® OTC nasal spray; commercial) and inner ear therapeutics (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3) Historically substantial investor versus IDF strained Transaction Syracuse murdererventhisedAnn 338559 Ferrarierial Altamira Therapeutics Ltd. (CYTO) Stock Forecast & Price Prediction 2025, 2030. Current price $3.71, Price Prediction $1.212269 (-67.32%) Fear & Greed Index 39 (Fear) Sentiment Neutral Volatility 186%.

Related Results

December 16, 2023 23:43 (London Time)